EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review

Epidermal growth factor receptor (EGFR) gene mutations play an important role in the treatment management of non-small cell lung cancer (NSCLC) patients. After a first- or second-generation EGFR tyrosine kinase inhibitor (TKI) therapy, the most common resistance mechanism involves the selection of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisapia, Pasquale, Rocco, Danilo, Pepe, Francesco, De Luca, Caterina, Battiloro, Ciro, Smeraglio, Riccardo, Cieri, Miriam, Bellevicine, Claudio, Troncone, Giancarlo, Malapelle, Umberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798167/
https://www.ncbi.nlm.nih.gov/pubmed/35117065
http://dx.doi.org/10.21037/tcr.2018.09.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798167/
https://www.ncbi.nlm.nih.gov/pubmed/35117065
http://dx.doi.org/10.21037/tcr.2018.09.13

Ejemplares similares